WaveWriter Alpha SCS for Chronic Pain
(MOSAIC Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to test a new method for managing chronic pain using a device that sends varying electrical pulses to the spine, known as Time Variant Pulse-SCS. The goal is to determine if these pulses can alleviate constant, hard-to-treat back or leg pain. It targets individuals who have experienced chronic pain for at least six months, including those who haven't found relief after back surgery or have ongoing back issues. As an unphased trial, this study offers patients the chance to explore innovative pain management solutions that may provide relief where other treatments have failed.
Do I need to stop taking my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that this device is safe for treating chronic pain?
Research has shown that spinal cord stimulation (SCS) therapies, such as the Time Variant Pulse (TVP)-SCS under study, are generally well-tolerated by individuals with chronic pain. In one study on dynamic SCS, participants reported fewer side effects compared to traditional methods. Additionally, a review of studies found that SCS treatments for chronic back and leg pain were safe, with few serious side effects.
Real-world data from 7,000 patients using similar SCS systems have demonstrated that these treatments are usually safe. Most side effects were mild and temporary, such as discomfort at the implant site. This suggests that TVP-SCS could be a safe option for managing chronic pain.12345Why are researchers excited about this trial?
Researchers are excited about the Time Variant Pulse Spinal Cord Stimulation (TVP-SCS) for chronic pain because it offers a new twist on spinal cord stimulation technology. Traditional spinal cord stimulators use constant electrical pulses to relieve pain, but TVP-SCS introduces varying pulse timings, which may more effectively mimic natural nerve signals, potentially leading to better pain relief. This innovative approach could offer hope for patients whose chronic pain hasn't responded well to existing treatments like opioids or conventional spinal cord stimulators.
What evidence suggests that this device is effective for chronic pain?
Research shows that spinal cord stimulation (SCS) using time-dynamic pulses (TDPs) can significantly reduce chronic pain. Studies have found that TDPs, used in a method called time variant pulse (TVP)-SCS, may provide longer-lasting pain relief compared to traditional methods. While both TDPs and regular stimulation ease pain, TDPs maintain effectiveness for a longer period before pain returns. Real-world data from thousands of patients support these findings, suggesting that TVP-SCS, which participants in this trial will receive, could be a promising option for individuals with chronic low back and leg pain.12467
Who Is on the Research Team?
Natalie M Bloom Lyons
Principal Investigator
Boston Scientific Corporation
Are You a Good Fit for This Trial?
This trial is for adults over 18 with persistent spinal pain syndrome (PSPS) Type I or II, including those with chronic back or leg pain lasting at least 6 months. Participants must be able to read and complete English questionnaires and have signed an approved consent form.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive time variant pulse (TVP)-SCS treatment using Boston Scientific SCS Systems
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Time Variant Pulse (TVP)-SCS
Find a Clinic Near You
Who Is Running the Clinical Trial?
Boston Scientific Corporation
Lead Sponsor
Michael F. Mahoney
Boston Scientific Corporation
Chief Executive Officer since 2016
MBA from Wake Forest University, BBA in Finance from the University of Iowa
Kenneth Stein
Boston Scientific Corporation
Chief Medical Officer since 2020
MD from Harvard Medical School, MMSc in Clinical Investigation from Harvard-MIT Division of Health Sciences and Technology